Published in Pharma Investments, Ventures and Law Weekly, August 7th, 2005
In exchange for the license rights, Azee agreed to pay a royalty on products derived from the licensed technology and issued shares of common stock. In addition, Azee will have the right to acquire the licensed technology upon the later achievement of certain agreed upon milestones and payment of additional consideration.
"We are very...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Investments, Ventures and Law Weekly